Revance Therapeutics Inc. (RVNC)

31.15
NASDAQ : Health Technology
Prev Close 30.75
Day Low/High 30.55 / 31.25
52 Wk Low/High 21.15 / 37.45
Avg Volume 314.90K
Exchange NASDAQ
Shares Outstanding 36.78M
Market Cap 1.13B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance To Participate In The UBS Global Healthcare Conference

Revance To Participate In The UBS Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in...

Revance Therapeutics Announces Two Recent Additions To Its Management Team

Revance Therapeutics Announces Two Recent Additions To Its Management Team

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its management team with the appointments of Conor Gallagher, Ph.

Revance Releases First Quarter 2018 Results

Revance Releases First Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the first quarter ended March 31, 2018.

Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell As SVP, General Counsel & Corporate Secretary

Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell As SVP, General Counsel & Corporate Secretary

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn...

Jim's Daily Rundown

Jim discusses the trade tariff deadline extension, Emerson Electric's earnings, last night's interview with Allergan CEO Brent Saunders, Goldman Sachs, 3M and more!

Revance Therapeutics Took the Least Resistance Path, Turned Lower

Revance Therapeutics Took the Least Resistance Path, Turned Lower

Let's see what else has weakened.

Allergan First Quarter Earnings

The market is looking past the positive results as the commentary surrounding the breakup overshadowed the earnings.

Pivotal SAKURA Phase 3 Clinical Data To Be Featured In Oral And Poster Presentations At The Aesthetic Meeting 2018

Pivotal SAKURA Phase 3 Clinical Data To Be Featured In Oral And Poster Presentations At The Aesthetic Meeting 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company's two pivotal SAKURA...

Revance Therapeutics To Release First Quarter 2018 Financial Results On Tuesday, May 8, 2018

Revance Therapeutics To Release First Quarter 2018 Financial Results On Tuesday, May 8, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release first quarter 2018 financial results on Tuesday, May 8,...

Revance Investor Day Highlights New Neuroscience Indications In Development

Revance Investor Day Highlights New Neuroscience Indications In Development

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, is holding its first Investor Day in New York City today.

Revance Therapeutics Stock Looks Ready for New Gains

Revance Therapeutics Stock Looks Ready for New Gains

I don't understand the fundamentals but I find the chart interesting.

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Revance Therapeutics: Cramer's Top Takeaways

Revance Therapeutics: Cramer's Top Takeaways

Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

Revance Therapeutics Expands Commercialization Team To Gear Up For Product Launch Of RT002 Injectable

Revance Therapeutics Expands Commercialization Team To Gear Up For Product Launch Of RT002 Injectable

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments of Dustin Sjuts as Vice...

Revance To Host Investor Day On April 19, 2018

Revance To Host Investor Day On April 19, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will host a live webcast of...

Revance To Participate In The Needham Healthcare Conference

Revance To Participate In The Needham Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the...

RVNC: Insiders vs. Shorts

RVNC: Insiders vs. Shorts

The most recent short interest data was recently released for the 02/28/2018 settlement date, and Revance Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 8.67 "days to cover" versus the median component at 4.17. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Allergan CEO: We Are Looking at All Options to Create Shareholder Value

Allergan CEO: We Are Looking at All Options to Create Shareholder Value

Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in two...

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Trimming Allergan

This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.

Weekly Roundup

Volatility picked up this week due to news from Washington.

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.

Mylan Shares Jump After Earnings Beat

Mylan Shares Jump After Earnings Beat

The pharmaceutical company unveiled a collaboration and license pact with Revance Therapeutics to develop and commercialize a proposed biosimilar or copy of Allergan's Botox.

Updates on Nucor and Allergan

Nucor looks to gain on the expected tariffs announcement, while separately we're downgrading Allergan.

Revance Releases Fourth Quarter And Full Year 2017 Results

Revance Releases Fourth Quarter And Full Year 2017 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced results for the fourth quarter and full year...

TheStreet Quant Rating: D (Sell)